There are only two primary paths that a development stage drugmaker with no recurring revenue can take to raise cash. It can either give up an ownership interest in one or more of its drugs in development, or it can give up an ownership interest in itself.
This share offering is Vertex’s third selling of common stock since the start of 2006. All told, Vertex has raised a total of at least $926 million in gross proceeds from dilutive stock and convertible note offerings as it and partner Johnson and Johnson
So what does this latest stock-offering mean for Vertex shareholders? Vertex was guiding for its 2008 net loss to be around $400 million, excluding certain charges. As things stand right now, Vertex isn’t giving any hint that telaprevir could be on the market before 2011, after its phase 3 studies are completed. Therefore, with only $832 million in cash and equivalents on its balance sheet at the end of June, it was going to need to raise some cash at some point in the future before telaprevir may be approved for marketing.
While no investor likes seeing their ownership interest in a company diluted, issuing new shares is almost the only way open for this type of company to raise cash. In several cases we’ve seen this year, like Theravance
The bottom line for this analyst is that with so much uncertainty swirling around the economy and the stock market, it makes sense for Vertex to build its cash reserves now rather than risk having to do so later at potentially worse terms in these tumultuous times.
Vertex and Exelixis are active picks of our market-beating Rule Breakers newsletter. You can check out all our other recommendations as well as get access to our message boards and exclusive content with a 30-day free trial.
Fool contributor Brian Lawler does not own shares of any company mentioned in this article. Johnson and Johnson is an active Income Investor pick. The Fool also owns shares of Exelixis. Check out our A+ disclosure policy, which makes us tell you these things.